TherapeuticsMD Announces Trading of Its Common Stock on the NYSE MKT Under Symbol “TXMD”
TherapeuticsMD, Inc. (OTCQB: TXMD) today announced that its common stock
has been approved for listing on the NYSE MKT, the premier U.S. equities
market for listing and trading of small growth companies. Trading is
expected to commence on the NYSE MKT on Tuesday, April 23, 2013, under
the ticker symbol “TXMD”.
“Becoming a NYSE MKT-listed company will provide enhanced trading
liquidity for current and future shareholders while enabling us to
attract a broader investor base. We view this as significant step in the
development of our company,” stated Rob Finizio, Chief Executive Officer
and co-founder of TherapeuticsMD.
“We are pleased to welcome TherapeuticsMD to the NYSE MKT family of
listed companies,” said Scott Cutler, EVP and Co-Head of U.S. Listings
and Cash Execution at NYSE Euronext. “TXMD will be joining other
growth-oriented companies in the U.S. taking advantage of the NYSE’s
advanced and innovative market model to offer a premier value for
listing and trading their stocks.”
About TherapeuticsMD
TherapeuticsMD, Inc. is a women’s healthcare product company focused on
creating and commercializing products targeted exclusively for women.
The Company manufactures and distributes branded and generic
prescription prenatal vitamins as well as over-the-counter vitamins and
cosmetics. The Company is currently conducting clinical trials necessary
for regulatory approval and commercialization of advanced hormone
therapy pharmaceutical products designed to alleviate the symptoms of
and reduce the health risks resulting from menopause-related hormone
deficiencies.
Forward-Looking Statements
Except for the historical information contained herein, the matters
set forth in this press release, including statements regarding
TherapeuticsMD’s expectations with respect to the timing of the
Company’s listing on the NYSE MKT and beliefs that becoming a NYSE
MKT-listed company will provide enhanced trading liquidity for current
and future shareholders while enabling it to attract a broader investor
base and is a significant step in its development, are forward-looking
statements within the meaning of the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially, including but not limited to: the risks
and uncertainties associated with economic and market conditions; risks
and uncertainties associated with TherapeuticsMD’s business and finances
in general; and other risks detailed in TherapeuticsMD’s annual report
on Form 10-K filed with the SEC on March 12, 2013, current report on
Form 8-K filed with the SEC on January 25, 2013, and other filings with
the SEC. These forward-looking statements are based on current
information that may change. Investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date of this press release. All forward-looking statements are qualified
in their entirety by this cautionary statement, and TherapeuticsMD
undertakes no obligation to revise or update any forward-looking
statement to reflect events or circumstances after the issuance of this
press release.
